Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.03.2017 | main topic

Cutaneous and visceral leishmaniasis during anti-TNFα therapy

verfasst von: Claudio Guarneri, M.D., Valentina Bevelacqua, M.D., Ph.D., Prof. James W. Patterson, M.D., Prof. Georgi Tchernev

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 3-4/2017

Einloggen, um Zugang zu erhalten

Summary

The long-term use of novel antipsoriatic systemic biotechnological drugs may increase susceptibility to opportunistic infections. Several cases of visceral leishmaniasis have been reported in immunosuppressed individuals, including those who have been treated with tumour necrosis factor alpha (TNFα) blocking agents. Simultaneous occurrence of cutaneous and visceral involvement has been more rarely recorded in the medical literature. Herein, we describe a case of mucosal leishmaniasis occurring in a farmer living in an endemic region, who was treated with golimumab because of psoriatic arthritis. This highlights the importance of recognizing cutaneous lesions as a first indicator of possible underlying kala-azar disease.
Vorheriger Artikel Radiation-induced lichen sclerosus of the vulva
Nächster Artikel Progredient dermatophytosis and nevus anemicus: a pathogenetic mediated relationship
Literatur
1.
Guarneri C, Tchernev G, Bevelacqua V, Lotti T, Nunnari G. The unwelcome trio: HIV plus cutaneous and visceral leishmaniasis. Dermatol Ther. 2016;29(2):88–91.CrossRefPubMed
2.
Guarneri C, Vaccaro M, Cannavò SP, Borgia F, Guarneri B. Erythematous-edematous-infiltrative plaque on the face: cutaneous angio-lupoid leishmaniasis. Eur J Dermatol. 2002;12(6):597–9.PubMed
3.
Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, Gualdi G, Guarneri C, Borsari S, Cassano N. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–7.CrossRefPubMed
4.
Ali T, Bronze MS, Kaitha S, Mahmood S, Ftaisi A, Stone J. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79–99.CrossRefPubMedPubMedCentral
5.
Amerio P, Amoruso G, Bardazzi F, Campanati A, Cassano N, Conti A, Gisondi P, Guarneri C, Mazzotta A, Piaserico S, Prestinari F, Prignano F, Zane C, de Simone C. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. J Dermatolog Treat. 2013;24(4):305–11.CrossRefPubMed
6.
Guarneri C, Guarneri F. Symmetrical cutaneous leishmaniasis. Acta Derm Venereol. 2005;85(3):281–2.PubMed
7.
Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27:305–18.CrossRefPubMed
8.
Alvar J, Velez ID, Bern C, Herrero M, Desieux P. WHO Leishmaniasis Control Team: leishmaniasis worldwide and global estimates of its incidence. PLOS ONE. 2012;7:e35671.CrossRefPubMedPubMedCentral
9.
Monge-Maillo B, Norman FF, Cruz I, Alvar J, López-Vélez R. Visceral leishmaniasis and HIV coinfection in the Mediterranean region. PLOS Negl Trop Dis. 2014;8(8):e3021.CrossRefPubMedPubMedCentral
10.
Borgia F, Vaccaro M, Guarneri F, Manfrè C, Cannavò SP, Guarneri C. Mucosal leishmaniasis occurring in a renal transplant recipient. Dermatology (Basel). 2001;202(3):266–7.CrossRef
11.
Celesia BM, Cacopardo B, Massimino D, Gussio M, Tosto S, Nunnari G, Pinzone MR. Atypical presentation of PKDL due to leishmania infantum in an HIV-infected patient with relapsing visceral leishmaniasis. Case Rep Infect Dis. 2014;2014:370286.PubMedPubMedCentral
12.
Català A, Roè E, Dalmau J, Pomar V, Munoz C, Yelamos O, Puig L. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature. Dermatology (Basel). 2015;230:204–7.CrossRef
13.
Vaccaro M, Magaudda L, Cutroneo G, Trimarchi F, Barbuzza O, Guarneri F, Guarneri B. Changes in the distribution of laminin α1 chain in psoriatic skin: immunohistochemical study using confocal laser scanning microscopy. Br J Dermatol. 2002;146(3):392–8.CrossRefPubMed
14.
Guarneri F, Guarneri C, Guarneri B. Biologic agents in the treatment of psoriasis. Recent Pat Inflamm Allergy Drug Discov. 2007;1(3):193–217.CrossRefPubMed
15.
Gisondi P, Amerio P, Amoroso GF, Antonucci VA, Bardazzi F, Buongiorno MR, Bruni P, Campanati A, Caproni M, Carlesimo M, Carrera CG, Cianchino G, Cimmino G, Costanzo A, Cozzani E, Dapavo P, D’amico D, De Simone C, Del Giglio M, Di Nuzzo S, Gai F, Galluccio AG, Goffredo A, Gualdi G, Guarneri C, Kokelj F, Lasagni C, Loconsole F, Longo V, Malagoli P, Miracapillo A, Mugheddu C, Parodi A, Pellegrino M, Peserico A, Piaserico S, Pistone G, Potenza C, Plumari A, Stingeni L, Strippoli D, Travaglino M, Girolomoni G. Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning. G Ital Dermatol Venereol. 2013;148(6 Suppl 1):1–10.PubMed
16.
Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47–57.CrossRefPubMed
17.
Tchernev G, Guarneri C, Bevelacqua V, Wollina U. Carcinoma cuniculatum in course of etanercept: blocking autoimmunity but propagation of carcinogenesis? Int J Immunopathol Pharmacol. 2014;27(2):261–6.CrossRefPubMed
18.
Cintolo M, Guarneri C, Lentini M. A case of molluscum contagiosum infection in a patient with Crohn’s disease, receiving combination therapy with azathioprine and adalimumab. J Crohns Colitis. 2015;9(7):593–4.CrossRefPubMed
19.
Guarneri C, Wollina U, Chokoeva A, Lotti TM, Tchernev G. A strange infiltrative plaque on the face. Braz J Infect Dis. 2016;20(2):214–5.CrossRefPubMed
20.
Postigo C, Llamas R, Zarco C, Rubio R, Pulido F, Costa JR, Iglesias L. Cutaneous lesions in patients with visceral leishmaniasis. J Infect. 1997;35:265–8.CrossRefPubMed
21.
Donati P, Paolino G, Panetta C, Muscardin L, Cota C, Giuliani M. Visceral leishmaniasis revealed by a squamous cell carcinoma in an HIV-1 infected patient. Infection. 2013;41:575–8.CrossRefPubMed
22.
Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter HR, López-Vélez R, Moreno J. The relationship betweeen leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21:334–59.CrossRefPubMedPubMedCentral
23.
Colebunders R, Depraetere K, Verstraeten T, Lambert J, Hauben E, Van Marck E, Maurer T, Banuls AL, Dujardin JC. Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection. J Am Acad Dermatol. 1999;41:847–50.CrossRefPubMed
24.
Van Grinsven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am. 2012;26:309–22.CrossRef
25.
De Simone C, Amerio P, Amoruso G, Bardazzi F, Campanati A, Conti A, Gisondi P, Gualdi G, Guarneri C, Leoni L, Loconsole F, Mazzotta A, Musumeci ML, Piaserico S, Potenza C, Prestinari F. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13(12):1673–82.CrossRefPubMed
26.
Bardazzi F, Amerio P, Amoruso G, Campanati A, Conti A, De Simone C, Gisondi P, Gualdi G, Guarneri C, Loconsole F, Mazzotta A, Musumeci ML, Odorici G, Piaserico S, Potenza C, Scudeller L, Alphard Study Group. Investigating psoriasis awareness among patients in Italy: validation of a questionnaire. Eur Rev Med Pharmacol Sci. 2014;18(22):3435–52.PubMed
27.
Tchernev G, Lotti T, Cardoso JC, Kanazawa N, Guarneri C, Wollina U. Cancer, infection and disturbances of the integrity of tissue homeostasis: the most significant triggers for molecular mimicry and autoimmunity in dermatology? Wien Med Wochenschr. 2014;164(13–14):245–6.CrossRefPubMed
28.
Guarneri C, Guarneri F, Risitano G, Lentini M, Vaccaro M. Solitary asymptomatic nodule of the great toe. Int J Dermatol. 2005;44(3):245–7.CrossRefPubMed
29.
Borgia F, Guarneri C, Guarneri F, Vaccaro M. Radiation recall dermatitis after docetaxel administration: absolute indication to replace the drug? Br J Dermatol. 2005;153(3):674–5.CrossRefPubMed
30.
Guarneri C, Cannavò SP. Dermacase. Can you identify this condition? Sarcoidosis. Can Fam Physician. 2012;58(8):859–61.PubMedPubMedCentral
31.
Cannavò SP, Lentini M, Magliolo E, Guarneri C. Cutaneous angiosarcoma of the face. J Eur Acad Dermatol Venereol. 2003;17(5):594–5.CrossRefPubMed
32.
Antinori S, Calattini S, Longhi E, Bestetti G, Piolini R, Magni C, Orlando G, Gramiccia M, Acquaviva V, Foschi A, Corvasce S, Colomba C, Titone L, Parravicini C, Cascio A, Corbellino M. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8‑year experience in Italy and review of the literature. Clin Infect Dis. 2007;44:1602–10.CrossRefPubMed
33.
34.
Di Masi F, Ursini T, Iannece MD, Chianura L, Baldasso F, Foti G, Di Gregorio P, Casabianca A, Storaci N, Nigro L, Colomba C, Marazzi MG, Todaro G, Tordini G, Zanelli G, Cenderello G, Acone N, Polilli E, Migliore S, Almi P, Pizzigallo E, Sagnelli E, Mazzotta F, Russo R, Manzoli L, Parruti G. Five-year retrospective Italian multicenter study of visceral leishmaniasis treatment. Antimicrob Agents Chemother. 2014;58(1):414–8.CrossRefPubMedPubMedCentral
35.
WHO. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. Geneva: WHO; 2010. 22–26 March 2010.
36.
Allenbach C, Launois P, Mueller C, Tacchini-Cottier F. An essential role for transmembrane TNF in the resolution of the inflammatory lesion induced by Leishmania major infection. Eur J Immunol. 2008;38:720–31.CrossRefPubMed
37.
Sivamani RK, Goodarzi H, Garcia MS, Raychaudhuri SP, Wehrli LN, Ono Y, Maverakis E. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol. 2013 Apr;44(2):121–40. doi:10.​1007/​s12016-012-8301-7. Review.
Metadaten
Titel
Cutaneous and visceral leishmaniasis during anti-TNFα therapy
verfasst von
Claudio Guarneri, M.D.
Valentina Bevelacqua, M.D., Ph.D.
Prof. James W. Patterson, M.D.
Prof. Georgi Tchernev
Publikationsdatum
01.03.2017
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 3-4/2017
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-016-0527-1

Weitere Artikel der Ausgabe 3-4/2017

Radiation-induced lichen sclerosus of the vulva

  • main topic

Pyoderma gangrenosum—a novel approach?

  • main topic

Trombiculiasis: not only a matter of animals!

  • main topic

Tinea capitis: a retrospective epidemiological comparative study

  • main topic

Global dermatology: challenges and changes?

  • editorial

Terra firma-forme dermatosis

  • main topic